Liminatus Pharma, Inc. Class A Common Stock (LIMN)

US — Healthcare Sector
Peers: ATHE  NNVC  GBIO  MURA  EVAX  BTAI  JSPR  DYAI  SABS  MAIA 

Automate Your Wheel Strategy on LIMN

With Tiblio's Option Bot, you can configure your own wheel strategy including LIMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LIMN
  • Rev/Share 0.0
  • Book/Share -0.378
  • PB -3.0822
  • Debt/Equity -0.1638
  • CurrentRatio 0.1695
  • ROIC 0.3736

 

  • MktCap 31530297.0
  • FreeCF/Share -0.4502
  • PFCF -3.0055
  • PE -19.4151
  • Debt/Assets 0.7557
  • DivYield 0
  • ROE 0.1436

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LIMN
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets.

Read More
image for news Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

About Liminatus Pharma, Inc. Class A Common Stock (LIMN)

  • IPO Date 2025-05-01
  • Website https://liminatuspharma.com
  • Industry Biotechnology
  • CEO Chris Kim
  • Employees 3
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.